Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
United Therapeutics
Age
15–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Between 15 and 80 years of age, inclusive, weigh at least 40 kg and have a diagnosis of PAH
Have stable disease as confirmed by recent right heart catheterization and a Baseline 6MWD of at least 250 meters
Have been receiving Remodulin for at least 90 days and at a stable dose for at least 30 days prior to the Baseline visit; the dose of Remodulin must be between 25-75 ng/kg/min, inclusive
Must be also receiving an endothelin receptor antagonist (ERA) and/or a phosphodiesterase-5 inhibitor (PDE-5i) for at least 90 days and have been at a stable dose for at least 30 days prior to Baseline
You may not be if
WHO functional class III and IV subjects will be excluded
